{"classes":[{"categories":[{"measurements":[{"comment":"Here, 'NA' signifies that upper limit of 95% confidence interval could not be estimated due to less number of participants with event.","groupId":"OG000","lowerLimit":"14.69","upperLimit":"NA","value":"23.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"PFS was defined as duration from the date of first dose to the date of disease progression or death, whichever occurs first, assessed according to the modified sixth IWWM (NCCN 2019) criteria. PD (at least 1 of the following): \\>=25% IgM increase in serum IgM with \\>=500 mg/dL increase from nadir (lowest serum IgM value at any time from baseline), confirmation needed if IgM was sole PD criterion; new lymph nodes \\>1.5 cm, \\>=50% increase in nadir in sum of product of diameters; 50% increase in longest diameter of previously identified node \\>1 cm in short axis; new splenomegaly; new extranodal disease; new/recurrent bone marrow involvement; new symptomatic disease (pleural effusion, Bing Neel syndrome, amyloidosis, light chain deposition, paraprotein mediated disorder).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"MEDIAN","populationDescription":"All treated analysis set included all enrolled participants who received at least 1 dose of study drug. Here, 'N' (overall number of participants analyzed) refers to the number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From day of first dose (Day 1) until PD or death (up to 49.3 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}